| 000 | 01621 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514183826.0 | ||
| 264 | 0 | _c20040617 | |
| 008 | 200406s 0 0 eng d | ||
| 022 | _a0903-1936 | ||
| 024 | 7 |
_a10.1183/09031936.04.00052504 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMunck, A | |
| 245 | 0 | 0 |
_aFollow-up of 452 totally implantable vascular devices in cystic fibrosis patients. _h[electronic resource] |
| 260 |
_bThe European respiratory journal _cMar 2004 |
||
| 300 |
_a430-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 | _aBlood Specimen Collection |
| 650 | 0 | 4 |
_aCatheters, Indwelling _xadverse effects |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aCystic Fibrosis _xtherapy |
| 650 | 0 | 4 |
_aFocal Infection _xepidemiology |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aParenteral Nutrition |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSepsis _xepidemiology |
| 650 | 0 | 4 |
_aThrombosis _xepidemiology |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aMalbezin, S | |
| 700 | 1 | _aBloch, J | |
| 700 | 1 | _aGerardin, M | |
| 700 | 1 | _aLebourgeois, M | |
| 700 | 1 | _aDerelle, J | |
| 700 | 1 | _aBremont, F | |
| 700 | 1 | _aSermet, I | |
| 700 | 1 | _aMunck, M R | |
| 700 | 1 | _aNavarro, J | |
| 773 | 0 |
_tThe European respiratory journal _gvol. 23 _gno. 3 _gp. 430-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1183/09031936.04.00052504 _zAvailable from publisher's website |
| 999 |
_c14781420 _d14781420 |
||